Â鶹´«Ã½

Skip to main content

Staff Profile

Professor Mike Waring

Chair of Medicinal Chemistry

  • Telephone: +44 (0)191 208 8591
  • Address: Â鶹´«Ã½ Centre for Cancer
    Chemistry
    School of Natural and Environmental Sciences
    Bedson Building
    Â鶹´«Ã½
    Â鶹´«Ã½ upon Tyne
    NE1 7RU
    UK
Background

Scopus ID: 7102782045; ORCID ID: 0000-0002-9110-8783 


Roles and Responsibilities

Mike's research interests are concerned with drug discovery using medicinal chemistry. He is Head of Medicinal Chemistry in the and Director of Academic Medicinal Chemistry for , CRUK's innovative organisation for therapeutic discovery. He is the Director of the EPSRC Centre for Doctoral Training in and Editor-in-Chief of .

Mike teaches Pharmacokinetics and Drug Metabolism in the Chemistry with Medicinal Chemistry (BSc and MChem) and Drug Chemistry (MSc) degree programmes.

Awards and Esteem

2022 European Federation of Medicinal Chemistry UCB-Ehrlich Prize

for excellence in medicinal chemistry

2018 American Chemical Society Hero of Chemistry

for the discovery of the mutant EGFR inhibitor osimertinib (Tagrisso), a treatment for resistant forms of non-small cell lung cancer.

2017 Royal Society of Chemistry Malcolm Campbell Medal

for excellence in biological and medicinal chemistry.

2017 Elected Fellow of the Royal Society of Chemistry

2014 Royal Society of Chemistry Inaugural Biological and Medicinal Chemistry Sector Lectureship

in recognition of outstanding contributions to medicinal chemistry.

2010 Royal Society of Chemistry Capps Green Zomaya Memorial Medal

for outstanding contributions to medicinal chemistry and outstanding success in bringing medicines to the clinic.

2010 European Federation of Medicinal Chemistry Prize

for an outstanding young medicinal chemist in industry (runner up).

Qualifications

BSc(Hons), First Class, in Chemistry 1996 (University of Manchester)

PhD in Organic Chemistry 1999 (University of Manchester) with Prof. T. J. Donohoe

Previous Positions

April 2011 – August 2015: Principal Scientist in Medicinal Chemistry at AstraZeneca, Alderley Park, UK.

July 2001 – March 2011: Team Leader in Medicinal Chemistry at AstraZeneca, Alderley Park, UK

January 2000 - July 2001: Post-doctoral researcher in the group of Prof. P. D. Magnus, University of Texas at Austin, USA.

 

Research

Anti-cancer drug discovery

Within the , we run a portfolio projects focused on identifying new molecules for novel cancer targets in areas of unmet medical need. We focus particularly on treatments for drug resistant cancers and to high value challenging targets such as protein-protein interactions. These projects involve cutting-edge structure based drug design and employ modern methods for hit generation and optimisation. In particular, we focus on fragment-based lead generation, DNA-encoded libraries and covalent inhibition.

Our group is part of Therapeutic Innovation, 's national innovation engine. Part of our portfolio is run in collaboration with through a strategic drug discovery alliance.

New methods of hit generation and lead optimisation

The identification of small-molecule ligands for protein targets remains a slow step in the medicinal chemistry and chemical biology fields. We are interested in developing new methods for hit generation and optimisation, which could be applied generally to make this process more successful by developing new technologies for finding hits and faster, more effective ways to optimise them. We are also interested in developing new chemical modalities that could lead to drugs for traditionally intractable targets.

Fraglites

In the group, we have developed , a set of small, halogenated probes that allow mapping of druggable sites on proteins and allow de novo hit generation. These compounds are now routinely employed in our projects and are becoming widely adopted in hit finding.

Published examples have shown how this approach can lead to novel inhibitors of CDK2, including the identification of allosteric binding sites and can differentiate the druggability of bromodomains .

DNA-encoded libraries

We employ DNA-encoded approaches to hit generation and lead optimisation using novel chemistry that we have developed in the group. In particular, our chemistry uses micellar catalysis as a way of carrying out highly efficient on-DNA chemistry and allows the construction of DNA-encoded libraries of the highest fidelity.

Thus far, we have developed , , , Sonogashira, Heck, and reactions on DNA. We have synthesised libraries exceeding 3 million encoded compounds to date.

These libraries are being screened for start points for drug discover in cancer, neurological and metabolic disorders.

We are also applying DNA-encoded methods to later stages of drug discovery such as fragment optimisation, with the potential to rapidly accelerate the discovery of new drugs.

Diversity-oriented synthesis

We are developing diversity-oriented methods for the synthesis of lead-like screening libraries, in particular using our paradigm for introducing scaffold diversity. This technology is used to find start points for novel drug targets.

Covalent inhibition

Covalent inhibition represents a highly attractive approach to new medicines through targeting proteins with irreversible binding. We are developing covalent inhibitors for therapeutic targets with novel warheads. This approach involves introduction of covalent warheads to existing scaffolds and development of inhibitors from covalent fragments.

Funding

Our Research is funded by , , , , , , , , and Â鶹´«Ã½. We are very grateful for their generous support. Funded opportunities will be advertised when available.

Teaching

CHY3109/3110/8822 - Stage 3 Medicinal Chemistry - Drug Metabolism and Toxicology.

Publications

  • Articles

    • Stewart HL, Bordoni C, Jennings CE, Al-Khawaldeh I, Martin MP, Noble RA, Phillips N, Pintar S, Prendergast L, Thomas HD, Wang L-Z, Watt JE, Wittner A, Bronowska AK, Cano C, Noble MEM, Wedge SR, Waring MJ. . Journal of Medicinal Chemistry 2026, 69(1), 533-552.
    • Odger J, Anderson MJ, Carton TP, Nguyen B, Foote K, Waring MJ. . Organic and Biomolecular Chemistry 2025, 23(28), 6745-6754.
    • Morese PA, Ahmad A, Martin MP, Noble RA, Pintar S, Wang LZ, Xu S, Lister A, Ward RA, Bronowska A, Noble MEM, Stewart HL, Waring MJ. . Communications Chemistry 2025, 8, 111.
    • Taylor CE, Roper G, Young R, Svensson F, Brunschweiger A, Butterworth S, Leach AG, Waring MJ. . RSC Medicinal Chemistry 2025, 16(10), 4774-4780.
    • Hope I, Martin MP, Jiang Z, Waring MJ, Noble MEM, Endicott JA, Tatum NJ. . Structure 2025, 33(11), 1971-1983.e3.
    • Anderson MJ, Carton T, Salvini CLA, Crawford JJ, Pairaudeau G, Waring MJ. . Chemistry: A European Journal 2024, 30(21), e202400239.
    • Pirie R, Stanway-Gordon HA, Stewart HL, Wilson KL, Paton S, Tyerman J, Cole DJ, Fowler K, Waring MJ. . RSC Medicinal Chemistry 2024, 15(9), 3125-3132.
    • Morese PA, Anthony N, Bodnarchuk M, Jennings C, Martin MP, Noble RA, Phillips N, Thomas HD, Wang LZ, Lister A, Noble MEM, Ward RA, Wedge SR, Stewart HL, Waring MJ. . Journal of Medicinal Chemistry 2023, 66(17), 12324-12341.
    • Graham JS, Stanway-Gordon HA, Waring MJ. . Chemistry - A European Journal 2023, 29(42), e202300603.
    • Salvini CLA, Darlot B, Davison J, Martin MP, Tudhope SJ, Turberville S, Kawamura A, Noble MEM, Wedge SR, Crawford JJ, Waring MJ. . Chemical Science 2023, 14(31), 8288-8294.
    • Stanway-Gordon HA, Odger JA, Waring MJ. . Bioconjugate Chemistry 2023, 34(4), 756-763.
    • Stewart HL, Bon M, Wills C, Martin MP, Wang L, Mackenzie ES, Wadell PG, Waring MJ. . Bioorganic and Medicinal Chemistry 2023, 91, 117387.
    • Castan IFSF, Madin A, Pairaudeau G, Waring MJ. . Bioorganic and Medicinal Chemistry 2022, 63, 116688.
    • Miller DC, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, Myers S, Newell DR, Noble RA, Phillips N, Rigoreau L, Thomas H, Tucker JA, Wang L-Z, Waring MJ, Wong A-C, Wedge SR, Noble MEM, Cano C. . Journal of Medicinal Chemistry 2022, 65(9), 6513-6540.
    • Stanway-Gordon HA, Graham JS, Waring MJ. . Angewandte Chemie International Edition 2022, 61(3), e202111927.
    • Davison G, Martin MP, Turberville S, Dormen S, Heath R, Heptinstall AB, Lawson M, Miller DC, Ng YM, Sanderson JN, Hope I, Wood DJ, Cano C, Endicott JA, Hardcastle IR, Noble MEM, Waring MJ. . Journal of Medicinal Chemistry 2022, 65(22), 15416-15432.
    • Andrews DM, Cartic S, Cosulich S, Divecha N, Faulder P, Flemington V, Kern O, Kettle JG, MacDonald E, McKelvie J, Pike KG, Roberts B, Rowlinson R, Smith JM, Stockley M, Swarbrick ME, Treinies I, Waring MJ. . Bioorganic and Medicinal Chemistry Letters 2022, 54, 116557.
    • Uguen M, Davison G, Sprenger LJ, Hunter JH, Martin MP, Turberville S, Watt JE, Golding BT, Noble MEM, Stewart HL, Waring MJ. . Journal of Medicinal Chemistry 2022, 65(16), 11322-11339.
    • Conole D, Hunter JH, Waring MJ. . Future Medicinal Chemistry 2021, 13, 173.
    • Castan IFSF, Graham JS, Salvini CLA, Stanway-Gordon HA, Waring MJ. . Bioorganic and Medicinal Chemistry 2021, 43, 116273.
    • Uguen M, Gai C, Sprenger LJ, Liu H, Leach AG, Waring MJ. . RSC Advances 2021, 11(48), 30229-30236.
    • Graham JS, Hunter JH, Waring MJ. . Journal of Organic Chemistry 2021, 86(23), 17257-17264.
    • Hunter JH, Anderson MJ, Castan IFSF, Graham JS, Salvini CLA, Stanway-Gordon HA, Crawford JJ, Madin A, Pairaudeau G, Waring MJ. . Chemical Science 2021, 12(27), 9475-9484.
    • Hunter JH, Potowski M, Stanway-Gordon HA, Madin A, Pairaudeau G, Brunschweiger A, Waring MJ. . Journal of Organic Chemistry 2021, 86(24), 17930-17935.
    • Picazo EMH, Heptinstall AB, Wilson DM, Cano C, Golding BT, Waring MJ. . Journal of Heterocyclic Chemistry 2021, 58(4), 947-951.
    • Al-Khawaldeh I, Aldred GG, Alyassiri M, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. . Journal of Medicinal Chemistry 2021, 64(14), 10001-10018.
    • Hunter JH, Prendergast L, Valente LF, Madin A, Pairaudeau G, Waring MJ. . Bioconjugate Chemistry 2020, 31(1), 149-155.
    • Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Abranyi-Balogh P, Brandao-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keseru GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA. . Nature Communications 2020, 11(1), 5047.
    • McAulay K, Hoyt EA, Thomas M, Schimpl M, Bodnarchuk MS, Lewis HJ, Barratt D, Bhavsar D, Robinson DM, Deery MJ, Ogg DJ, Bernardes GJL, Ward RA, Waring MJ, Kettle JG. . Journal of the American Chemical Society 2020, 142(23), 10358–10372.
    • Bosma R, Wang Z, Kooistra AJ, Bushby N, Kuhne S, van den Bor J, Waring MJ, de Graaf C, de Esch IJ, Vischer HF, Sheppard RJ, Wijtmans M, Leurs R. . Journal of Medicinal Chemistry 2019, 62(14), 6630-6644.
    • Bosma R, Soddart LA, Georgi V, Bouzo-Lorenzo M, Bushby N, Inkoom NL, Waring MJ, Briddon SJ, Vischer HF, Sheppard RJ, Fernandez-Montalvan A, Hill SJ, Leurs R. . Scientific Reports 2019, 9, 7906.
    • Wood D, Lopez-Fernandez JD, Knight LE, Al-Khawaldeh I, Gai C, Lin S, Martin MP, Miller DC, Cano C, Endicott JA, Hardcastle IR, Noble MEM, Waring MJ. . Journal of Medicinal Chemistry 2019, 62(7), 3741-3752.
    • Golding BT, Waring MJ. . Expert Opinion on Drug Discovery 2018, 13(7), 583-585.
    • Scott JS, Waring MJ. . Bioorganic & Medicinal Chemistry 2018, 26(11), 3006-3015.
    • McCoull W, Cheung T, Anderson E, Barton P, Burgess J, Byth K, Cao Q, Castaldi MP, Chen H, Chiarparin E, Carbajo RJ, Code E, Cowan S, Davey PR, Ferguson AD, Fillery S, Fuller NO, Gao N, Hargreaves D, Howard MR, Hu J, Kawatkar A, Kemmitt PD, Leo E, Molina DM, O'Connell N, Petteruti P, Rasmusson T, Raubo P, Rawlins PB, Ricchiuto P, Robb GR, Schenone M, Waring MJ, Zinda M, Fawell S, Wilson DM. . ACS Chemical Biology 2018, 13(11), 3131-3141.
    • Osher EL, Castillo F, Elumalai N, Waring MJ, Pairaudeau G, Tavassoli A. . Bioorganic & Medicinal Chemistry 2018, 26(11), 3034-3038.
    • England RM, Hare JI, Barnes J, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, Ashford MB. . Journal of Controlled Release 2017, 247, 73-85.
    • Xia L, de Vries H, Lenselink EB, Louvel J, Waring MJ, Cheng L, Pahlén S, Petersson MJ, Schell P, Olsson RI, Heitman LH, Sheppard RJ, IJzerman AP. . Journal of Medicinal Chemistry 2017, 60(23), 9545-9564.
    • Hothersall JD, Guo D, Sarda S, Sheppard RJ, Chen H, Keur W, Waring MJ, IJzerman AP, Hill SJ, Dale IL, Rawlins PB. . Molecular Pharmacology 2017, 91(1), 25-38.
    • McCoull W, Abrams RD, Anderson E, Blades K, Barton P, Box M, Burgess J, Byth K, Cao Q, Chuaqui C, Carbajo RJ, Cheung T, Code E, Ferguson AD, Fillery S, Fuller NO, Gangl E, Gao N, Grist M, Hargreaves D, Howard MR, Hu J, Kemmitt PD, Nelson JE, OConnell N, Prince DB, Raubo P, Rawlins PB, Robb GR, Shi J, Waring MJ, Whittaker D, Wylot M, Zhu X. . Journal of Medicinal Chemistry 2017, 60(10), 4386-4402.
    • Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale E, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Mendez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y. . Nature Chemical Biology 2016, 12, 1097-1104.
    • Bradbury RH, Callis R, Carr GR, Chen H, Clark E, Feron L, Glossop S, Graham MA, Hattersley M, Jones C, Lamont SG, Ouvry G, Patel A, Patel J, Rabow AA, Roberts CA, Stokes S, Stratton N, Walker GE, Ward L, Whalley D, Whittaker D, Wrigley G, Waring MJ. . Journal of Medicinal Chemistry 2016, 59(17), 7801-7817.
    • England RM, Hare JI, Kemmitt PD, Treacher K, Waring MJ, Barry ST, Alexander C, Ashford M. . Polymer Chemistry 2016, 7(28), 4609-4617.
    • Rhyasen GW, Hattersley M, Yao Y, Dulak A, Wang W, Petteruti P, Dale I, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh T, Rabow AA, Dry J, Reimer C, Lyne P, Mills GB, Fawell S, Waring MJ, Zinda M, Clark E, Chen H. . Molecular Cancer Therapeutics 2016, 15(11), 2563-2574.
    • Raubo P, Andrews DM, McKelvie JC, Robb GR, Smith JM, Swarbirck ME, Waring MJ. . Bioorganic & Medicinal Chemistry Letters 2015, 25(16), 3189-3193.
    • Waring MJ, Baker DJ, Bennett SNL, Dossetter AG, Fenwick M, Garcia R, Georgsson J, Groombridge SD, Loxham S, MacFaul PA, Maskill KG, Morgan D, Morrell J, Pointon H, Robb GR, Smith DM, Stokes S, Wilkinson G. . MedChemComm 2015, (6), 1024-1029.
    • Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie W, Pickett SD, Wang J, Wallace O, Weir A. . Nature Reviews Drug Discovery 2015, 14, 475-486.
    • Waring MJ, Bennett SNL, Campbell L, Hallam S, Martin NG, Tickner C. . Tetrahedron Letters 2015, 56(34), 4904-4907.
    • Cumming JG, Finlay MRV, Giordanetto F, Hemmerling M, Lister T, Sanganee H, Waring MJ. . Future Medicinal Chemistry 2014, 6(5), 515-527.
    • Waring MJ, Andrews DM, Faulder PF, Flemington V, McKelvie JC, Maman S, Preston M, Raubo P, Robb GR, Roberts K, Rowlinson R, Smith JM, Swarbrick ME, Treines I, Winter JG, Wood RJ. . Chemical Communications 2014, 50(40), 5388-5390.
    • Finlay MRV, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DAE, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. . Journal of Medicinal Chemistry 2014, 57(20), 8249-8267.
    • Gill DM, McLay N, Waring MJ, Wilkinson CT, Sweeney JB. . Synlett 2014, 25(12), 1756-1756.
    • Ward RA, Anderton M, Ashton S, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross D, Debreczeni JE, Eberlein C, Finlay MRV, Grist M, Hill GB, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ. Structure and reactivity based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem 2013, 56, 7025.
    • McKerrecher D, Waring MJ. Property-Based Design in the Optimisation of Benzamide Glucokinase Activators: From Hit to Clinic. Progr. Med. Chem 2013, 52, 1.
    • McKerrecher D, Waring MJ. Property based design in the optimisation of glucokinase activators: from hit to clinic. Progr. Med. Chem 2013, 52, 1.
    • Waring MJ, Bennett SNL, Campbell L, Davies RDM, Hargreaves D, MacFaul P, Martin NG, Ogg D, Robb GR, Wilkinson G, Wood JM. Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets – the discovery of AZD3651 and AZD9485. Med. Chem. Commun 2013, 4, 663.
    • Waring MJ, Birch AM, Birtles S, Buckett LK, Butlin RJ, Campbell L, MorentinGutierrez P, Kemmitt P, Leach AG, MacFaul P, ODonnell C, Turnbull AV. Optimisation of biphenylacetic acid inhibitors of diacylglycerol acetyl transferase 1 – the discovery of AZD2353. Med. Chem. Commun 2013, 4, 159.
    • Waring MJ, Bennett SNL, Campbell L, Davies RDM, Gerhardt S, Hargreaves D, Martin NG, Robb GR, Wilkinson G. Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content. Med. Chem. Commun 2013, 4, 657.
    • Plowright AT, Barton P, Bennett S, Birch AM, Birtles S, Buckett LK, Butlin RJ, Davies RDM, Ertan A, MorentinGutierrez P, Kemmitt PD, Leach AG, Svensson PH, Turnbull AV, Waring MJ. Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1. Med. Chem. Commun 2013, 4, 151.
    • Robb GR, McKerrecher D, Newcombe NJ, Waring MJ. . Drug Discovery Today 2013, 18(3-4), 141-147.
    • Bonn P, Brink DM, Faegerhag J, Jurva U, Robb GR, Schnecke V, SvenssonHenriksson A, Waring MJ, Westerlund C. The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold. Bioorg. Med. Chem. Lett 2012, 22, 7302.
    • Moss T, Addie MS, Nowak T, Waring MJ. Room-temperature palladium-catalyzed coupling of heteroaryl amines with aryl or heteroaryl bromides. Synlett 2012, 23, 285.
    • Waring MJ, Clarke DS, Fenwick MD, Godfrey L, Groombridge S, Johnstone C, McKerrecher D, Pike KG, Rayner J, Robb GR, Wilson I. Property based optimisation of glucokinase activators – the discovery of the Phase IIb candidate AZD1656. Med. Chem. Commun 2012, 3, 1077.
    • Luker T, Alcaraz L, Chohan KK, Blomberg N, Brown DS, Butlin RJ, Elebring T, Griffin AM, Guile S, St-Gallay S, Swahn BM, Swallow S, Waring MJ, Wenlock MC, Leeson PD. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. Bioorg. Med. Chem. Lett 2011, 21, 5673.
    • Waring MJ, Brogan IJ, Coghlan M, Johnstone C, Jones HB, Leighton B, McKerrecher D, Pike KG, Robb GR. Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators. Med. Chem. Commun 2011, 2, 771.
    • Waring MJ, Johnstone C, McKerrecher D, Pike KG, Robb GR. Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092. Med. Chem. Commun 2011, 2, 775.
    • Tetlow DJ, Hennecke U, Raftery J, Waring MJ, Clarke DS, Clayden J. Sequential double α-arylation of N-allylureas by asymmetric deprotonation and N→C Aryl Migration. Organic Lett 2010, 12, 5442.
    • Waring MJ. . Expert Opinion on Drug Discovery 2010, 5(3), 235-248.
    • Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates - molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett 2009, 19, 2844.
    • Clark JS, Northall JM, Marlin F, Nay B, Wilson C, Blake AJ, Waring MJ. Synthetic studies on the cornexistins: synthesis of (±)-5-epi-hydroxycornexistin. Org. Biomol. Chem 2008, 6, 4012.
    • Andrews DM, Stokes ESE, Carr GR, Matusiak ZS, Roberts CA, Waring MJ, Brady MC, Chresta CM, East SJ. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett 2008, 18, 2580.
    • Boyd S, Campbell L, Liao W, Meng Q, Peng Z, Wang W, Waring MJ. A one step synthesis of 1-alkylpyrazolo[5,4-d]pyrimidines. Tetrahedron Lett 2008, 49, 7395.
    • Waring MJ, Johnstone CJ. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett 2007, 17, 1759.
    • Donohoe TJ, Mitchell L, Waring MJ, Helliwell M, Bell A, Newcombe NJ. Scope of the directed dihydroxylation: application to cyclic homoallylic alcohols and trihaloacetamides. Org. Biomol. Chem 2003, 1, 2173.
    • Donohoe TJ, Blades K, Moore PR, Waring MJ, Winter JJG, Helliwell M, Newcombe NJ, Stemp G. Directed dihydroxylation of cyclic allylic alcohols and trichloroacetamides using OsO4/TMEDA. J. Org. Chem 2002, 67, 7946.
    • Magnus P, Waring MJ, Ollivier C, Lynch V. Stereoselective synthesis of the bicyclo[5.3.0]decane portion of the diterpene antibiotic guanacastepene using a pyrylium-ylide [5+2] cycloaddition reaction. Tetrahedron Lett 2001, 42, 4947.
    • Donohoe TJ, Mitchell L, Waring MJ, Helliwell M, Bell A, Newcombe NJ. Homoallylic alcohols and trichloroacetamides as hydrogen bond donors for directed dihydroxylation. Tetrahedron Lett 2001, 42, 8951.
    • Donohoe TJ, Waring MJ, Newcombe NJ. Enhanced stereoselectivity in the catalytic dihydroxylation of acyclic allylic alcohols. SynLett 2000, 149.
    • Magnus P, Payne AH, Waring MJ, Scott DA, Lynch V. Conversion of α,β-unsaturated ketones into α-hydroxy ketones using an MnIII catalyst, phenylsilane and dioxygen: acceleration of conjugate hydride reduction by dioxygen. Tetrahedron Lett 2000, 41, 9725.
    • Magnus P, Waring MJ, Scott DA. Conjugate reduction of α,β-unsaturated ketones using an MnIII catalyst, phenylsilane and isopropyl alcohol. Tetrahedron Lett 2000, 41, 9731.
    • Donohoe TJ, Waring MJ, Newcombe NJ. syn Stereocontrol in the directed dihydroxylation of acyclic allylic alcohols. Tetrahedron Lett 1999, 40, 6881.
    • Donohoe TJ, Blades K, Helliwell M, Waring MJ, Newcombe NJ. The synthesis of (+)-Pericosine B. Tetrahedron Lett 1998, 39, 8755.
    • Donohoe TJ, Harji RR, Moore PR, Waring MJ. Applications of stoichiometric organotransition metal complexes in organic synthesis. J. Chem. Soc., Perkin Trans. 1 1998, 819.
    • Donohoe TJ, Moore PR, Waring MJ, Newcombe NJ. The directed dihydroxylation of allylic alcohols. Tetrahedron Lett 1997, 38, 5027.

  • Book Chapters

    • Anderson MJ, Castan IFSF, Graham JS, Hassan H, Odger J, Salvini CLA, Taylor C, Waring MJ. Advancements in DEL-Compatible Chemical Reactions. Springer, 2022, pp.1 - 59. In Preparation.
    • Bordoni C, Brough DJ, Davison G, Hunter JH, Lopez-Fernandez JD, McAdam K, Miller DC, Morese PA, Papaioannou A, Uguen M, Ratcliffe P, Sitnikov N, Waring MJ. . In: Schnider P, ed. The Medicinal Chemist’s Guide to Solving ADMET Challenges. Cambridge: Royal Society of Chemistry, 2021, pp.403-492.
    • Waring MJ. The discovery of osimertinib (TAGRISSOTM): an irreversible inhibitor of activating and T790M resistance forms of the epidermal growth factor receptor tyrosine kinase. In: Fischer, J, ed. Successful Drug Discov. Wiley, 2018, pp.341. In Preparation.
    • Waring MJ, Leach AG, Miller DC. . In: Thermodynamics and Kinetics of Drug Binding. Wiley Blackwell, 2015, pp.191-210.

  • Edited Book

    • Waring MJ, ed. . Springer International Publishing, 2018.

  • Patent

    • Bradbury RH, Rabow AA, Waring MJ, McCabe JF, Glossop SC, Mahmood A, Cotter ZA. . 04/02/2016.